Free Trial

Roth Capital Analysts Cut Earnings Estimates for Curaleaf

Curaleaf logo with Medical background
Remove Ads

Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Investment analysts at Roth Capital cut their Q3 2025 earnings per share (EPS) estimates for Curaleaf in a research note issued on Tuesday, March 4th. Roth Capital analyst W. Kirk now forecasts that the company will post earnings per share of ($0.06) for the quarter, down from their prior forecast of ($0.05). Roth Capital has a "Strong-Buy" rating on the stock. The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Roth Capital also issued estimates for Curaleaf's Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.23) EPS and FY2026 earnings at ($0.19) EPS.

Curaleaf (OTCMKTS:CURLF - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.09. The firm had revenue of $331.05 million during the quarter, compared to analyst estimates of $331.87 million. Curaleaf had a negative net margin of 14.82% and a negative return on equity of 13.67%.

Curaleaf Trading Down 2.0 %

OTCMKTS CURLF traded down $0.02 during trading on Thursday, hitting $0.99. The stock had a trading volume of 985,502 shares, compared to its average volume of 748,980. The stock has a market capitalization of $654.02 million, a price-to-earnings ratio of -3.41 and a beta of 0.57. The stock has a 50 day simple moving average of $1.41 and a 200 day simple moving average of $2.13. Curaleaf has a one year low of $0.88 and a one year high of $6.40. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.51 and a current ratio of 1.11.

Remove Ads

Curaleaf Company Profile

(Get Free Report)

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.

Featured Articles

Earnings History and Estimates for Curaleaf (OTCMKTS:CURLF)

Should You Invest $1,000 in Curaleaf Right Now?

Before you consider Curaleaf, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.

While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

5 Stocks to BUY NOW in February 2025

5 Stocks to BUY NOW in February 2025

With the market holding strong, inflation concerns persisting, and major earnings reports ahead, these stock picks could be game-changers for your portfolio!

Recent Videos

Best ETFs for Spring 2025: Strong and Steady Investing
Is There Still Money in AI? How to Invest in the Next Big Wave
AMD at Rock Bottom? Analysts Predict a MAJOR Rebound!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads